Porcilis PCV ID
Porcine circovirus vaccine (inactivated)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Porcilis PCV ID. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Porcilis PCV ID.
For practical information about using Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Porcilis PCV ID
|
Agency product number |
EMEA/V/C/003942
|
Active substance |
porcine circovirus type 2 ORF2 subunit antigen
|
International non-proprietary name (INN) or common name |
Porcine circovirus vaccine (inactivated)
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA07
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V.
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
28/08/2015
|
Contact address |
Wim de Körverstraat 35 |
Product information
09/09/2021 Porcilis PCV ID - EMEA/V/C/003942 - II/0005/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for suidae
-
Inactivated viral vaccines
Therapeutic indication
For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by PCV2 infection. To reduce loss of daily weight gain and mortality associated with PCV2 infection.